CBL-0206
Localized Fat Reduction (Asia-Pacific)
Phase 2 (Planned)Active
Key Facts
Indication
Localized Fat Reduction (Asia-Pacific)
Phase
Phase 2 (Planned)
Status
Active
Company
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals is a high-value, publicly traded biotech focused on developing breakthrough small-molecule drugs for aesthetic and chronic inflammatory conditions. Its core achievement is the development of CBL-514, a first-in-class injectable for localized fat reduction with a novel apoptosis mechanism, which has advanced into late-stage clinical trials. The company's strategy targets large, underserved markets where current treatments are inadequate, leveraging its proprietary platform and strategic base in Taiwan for global expansion.
View full company profile